

# **Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer**

**A. H. Zedan, P. J. S. Osther, J. Assenholt, J. S. Madsen, T. F. Hanse**

**Table S2: The association of baseline circulating miRs with OS and rPFS as demonstrated by Kaplan-Meier survival curves**

	ABI cohort		DOC cohort	
	rPFS	OS	rPFS	OS
	<i>p</i> -value	<i>p</i> -value	<i>p</i> -value	<i>p</i> -value
miR-93-5p	0.08	0.11	0.59	0.55
miR-125b-1-5p	0.56	0.52	0.97	0.52
miR-141-3p	<b>0.03</b>	0.18	<b>&lt;0.01</b>	<b>&lt;0.01</b>
miR-375-3p	0.12	0.33	<b>&lt;0.01</b>	<b>&lt;0.01</b>
miR-221-3p	0.85	0.09	0.801	0.65

ABI: abiraterone; DOC: docetaxel. Statistically significant values are in bold writing